| Gesamtstichprobe N (%) |
|
|---|---|
| Patientenanzahl | 30 (100,0) |
| Mittleres Alter in Jahren (Min.–Max.) | 52,8 (19–77) |
| Mittlerer Body-Mass-Index in kg/m2 (Min.–Max.) | 28,7 (20,1–39,9) |
| Geschlecht | |
| Weiblich | 9 (30,0) |
| Männlich | 21 (70,0) |
| Häufigste Komorbiditäten | |
| Arterielle Hypertonie | 13 (43,3) |
| Adipositas | 10 (33,3) |
| Nikotinabusus | 10 (33,3) |
| Diabetes mellitus | 3 (10,0) |
| Verwendete Lokaltherapien | |
| Nein | 5 (16,7) |
| Ja | 25 (83,3) |
| Calcipotriol in Kombination mit Betamethason | 11 (36,7) |
| Calcipotriol | 6 (20,0) |
| Glukokortikoid | 2 (6,7) |
| Hautpflegeprodukte | 6 (20,0) |
| Verwendete Systemtherapien | |
| Nein | 7 (23,3) |
| Ja | 23 (76,7) |
| Biologika | 12 (40,0) |
| – TNF-α-Inhibitor | 1 (3,3) |
| – Certolizumab | 1 (3,3) |
| – Interleukin-12/23-Inhibitor | 1 (3,3) |
| – Ustekinumab | 1 (3,3) |
| – Interleukin-17A-Inhibitor | 4 (13,3) |
| – Secukinumab | 1 (3,3) |
| – Ixekizumab | 3 (10,0) |
| – Interleukin-23-Inhibitor | 6 (20,0) |
| – Tildrakizumab | 2 (6,7) |
| – Risankizumab | 2 (6,7) |
| – Guselkumab | 2 (6,7) |
| Konventionelle Systemtherapie | 11 (36,6) |
| – Methotrexat | 7 (23,3) |
| – Dimethylfumarat | 4 (13,3) |
Min. Mindestens, Max. Maximal, TNF-α Tumornekrosefaktor-α